Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Published on: February 23, 2012
ASH advocacy to prevent drug shortages continues to make progress.
ASH applauds the actions announced by the FDA to address the shortages of methotrexate and Doxil, but cautions more needs to be done to fully combat shortages of life-saving hematologic drugs. ASH will continue to support legislative and regulatory changes that will give FDA the authority and resources it needs to effectively prevent and mitigate future drug shortages. ASH will also continue to track methotrexate and Doxil supplies closely and will notify the membership as soon as additional information is available.
Please visit the ASH Drug Update page for more details about these shortages and other hematologic drug shortages. If you have any additional questions and/or concerns about any hematologic drug shortages, please contact ASH Government Relations Manager, Stephanie Kaplan at 202-776-0544 or email@example.com.
Support the mission of ASH and help move hematology forward.
Become part of a global network of more than 15,000 hematologists working to conquer blood diseases.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology